NAD+ Delivery Methods Face Off — Does How You Take It Actually Matter
A new webinar tackles the real question in NAD+ supplementation: whether pills, injections, or pens produce meaningfully different health outcomes.
Summary
NAD+ is one of longevity medicine's most talked-about molecules, linked to cellular repair and energy metabolism — and its levels decline with age. But as the market floods with capsules, IV infusions, pens, and liposomal formulas, the critical question isn't whether NAD+ matters, but how best to deliver it. Longevity.Technology and Bio Atelier are hosting a webinar on May 20th bringing together clinicians and industry founders to compare delivery systems head-to-head. The session will examine absorption rates, patient compliance, formulation quality, and whether different routes produce real-world differences in how people feel and function. It marks a broader maturation in the longevity space — moving past hype toward operational, evidence-grounded questions about what actually works in practice.
Detailed Summary
NAD+ has emerged as one of the most commercially visible molecules in longevity medicine, moving from exclusive IV clinics and biohacker circles into mainstream wellness culture. Yet despite widespread adoption, a foundational question remains unresolved: does the delivery method — pill, injection, or pen — significantly affect outcomes? That question is now driving serious clinical conversation.
Longevity.Technology and Bio Atelier are hosting a live webinar on May 20th titled 'NAD Explained: Pills vs Injections vs Pens – What Actually Works?' The session convenes clinicians and industry founders to examine the practical realities of NAD+ supplementation beyond marketing narratives. Speakers include Dr Rachna Murthy on clinical applications, and Bio Atelier cofounders Maila Reeves and Trinity Gardiner on formulation, implementation, and patient experience.
The core issues under discussion include bioavailability differences across delivery routes, absorption rates, and the everyday friction of maintaining a protocol. The webinar will also feature a live demonstration of Bio Atelier's NAD+ pen — a subcutaneous self-injection device positioned as a middle ground between clinic-based IV infusions and standard oral supplements. The company emphasizes its mannitol-free, clinical-grade formulation as a differentiator.
The event reflects a meaningful shift in how the longevity field is maturing. Early enthusiasm around NAD+ focused on the molecule itself — its role in DNA repair, mitochondrial function, and sirtuin activation. Now, attention is turning to translational questions: how do lab findings map onto real patient outcomes, and which formats support long-term adherence?
Caveats apply. This webinar is co-hosted by a commercial partner with a product to present, which introduces potential bias even if framed as educational. No new clinical trial data is being released. Viewers should treat insights as expert opinion and seek peer-reviewed evidence before making protocol decisions.
Key Findings
- NAD+ levels decline with age; delivery method may determine how effectively supplementation restores them
- Oral pills, subcutaneous pens, and IV infusions differ in bioavailability and patient adherence — outcomes may vary accordingly
- Clinical conversations are shifting from 'does NAD+ work' to 'which format works best for which patient'
- Formulation quality, including excipient choices like mannitol-free composition, is emerging as a key differentiator
- Long-term protocol compliance may matter as much as the delivery route itself
Methodology
This is a news and promotional article from Longevity.Technology announcing an upcoming industry webinar co-hosted with a commercial partner, Bio Atelier. It does not report original research findings; insights are based on expert clinical opinion and industry experience. Source credibility is moderate — Longevity.Technology is a recognized longevity media platform, but commercial co-hosting introduces potential bias.
Study Limitations
This article is an event announcement, not a research report, so no new clinical data is presented. Bio Atelier's involvement as a commercial co-host means product promotion may shape the framing of 'educational' content. Readers should verify claims about absorption and bioavailability against peer-reviewed literature before changing supplementation protocols.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.